Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)
Funding Amount
$1,600,000 total
Deadline
Forecast — dates not yet posted
Number of Awards
2
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- City & township governments
- County governments
- Nonprofits (501(c)(3))
- State governments
- Special district governments
- Small businesses
- School districts
- Nonprofits without 501(c)(3) status
Geography
- Non-domestic (non-U.S.) components of U.S.
Not eligible / not funded
- Not eligible: Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-Eligible ApplicantsNon-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
- Not eligible: Organizations are not eligible to apply.
- Not eligible: Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Overview
NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that will develop, validate and demonstrate the utility of advanced 3-D tissue models for testing the efficacy of various therapeutic modalities, including small molecules and biologics and accelerate the discovery and development of new therapeutics across different diseases. The initiative will develop advanced 3-D drug screening models adaptable to high throughput assays. These non-animal models are expected to mimic structural, biochemical and mechanical properties of tissue that are representative of a drug’s behavior in a body, resulting in improved predictive accuracy. This is an expansion upon the work conducted under previous NOFOs, RFA-TR-17-007, RFA-TR-19-020 and RFA-TR-21-015, that have focused on development of 3-D skin and other tissue models for drug screening. The applicants are required to utilize the 3-D modeling/drug screening expertise and infrastructure available at the NCATS 3-D Bioprinting laboratory. 3-D tissue models in a well-based drug screening platform should be as complex as necessary to achieve physiological/pharmacological relevance, and as simple as possible to make the models robust, reliable and amenable to drug screening. Grant authorities that allow NCATS to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: RFA-TR-25-016
- Total Funding: $1,600,000
- Expected Awards: 2
- Instrument: cooperative_agreement
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-Eligible ApplicantsNon-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Focus Areas & Funding Uses
Fields of Work
- Science research
- Nonprofits
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed). Now let's win it.